Jardiance: Another SGLT-2 Inhibitor Is Approved

Page Changed: Invokana, Farxiga, Jardiance: A New Class of Questionable Drugs for Type 2 Text Added: Jardiance is the same empagliflozin that the FDA did not approve a year ago supposedly because of unspecified manufacturing problems. It was approved in August 2014. Like the other drugs we just discussed Jardiance causes urinary tract infections and vaginal, and penile yeast infection. The FDA is also demanding post-marketing cardiovascular tests, so it is likely that the same disturbing signals emerged in its clinical trials as emerged with the other drugs. It too is not recommended for people with kidney disease. It is not known whether a cancer signal appeared in its clinical trials. But since these trials only involved a total of 4,500 people and did not last more than a few years, the cancer signal seen in other drugs in the same class should not be ignored.